<DOC>
	<DOCNO>NCT00331422</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving chemotherapy drug surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study well give paclitaxel together carboplatin surgery work treat patient advanced ovarian epithelial cancer , fallopian tube cancer , primary peritoneal cavity cancer .</brief_summary>
	<brief_title>Carboplatin , Paclitaxel , Surgery Treating Patients With Advanced Ovarian Epithelial , Fallopian Tube , Primary Peritoneal Cavity Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether least 50 % patient advanced ovarian epithelial , fallopian tube , primary peritoneal cavity cancer able achieve optimal cytoreduction ( &lt; 1 centimeter remain disease ) neoadjuvant chemotherapy comprise paclitaxel carboplatin . Secondary - Determine frequency severity toxicity associate regimen patient high-risk surgical candidate patient unlikely achieve optimal surgical cytoreduction . - Determine extreme drug resistance assay profile change neoadjuvant chemotherapy . - Determine thrombospondin-1 ( TSP-1 ) , tumor protein 53 ( p53 ) , tumor vessel density change administration neoadjuvant chemotherapy . - Assess quality life patient receive neoadjuvant chemotherapy . - Obtain estimate tumor response administration neoadjuvant chemotherapy . - Determine whether serum cancer antigen 125 ( CA-125 ) time cytoreduction associate ability optimally reduce patient . OUTLINE : This open-label study . Patients receive paclitaxel intravenously ( IV ) 3 hour carboplatin IV 30 minute day 1 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . Within 4-6 week fourth course chemotherapy , patient undergo interval cytoreductive surgery . Patients unable undergo surgery receive 2 additional course chemotherapy re-evaluated surgery sixth course chemotherapy . Within 4 week surgery , patient receive 2 additional course chemotherapy . Quality life assess periodically . Tumor sample obtain via laparoscopic percutaneous biopsy prior begin chemotherapy interval cytoreduction . Tissue examine immunohistochemistry stain p53 , TSP-1 , microvessel density ( CD31 ) , angiogenesis , membrane protein BCL-2 , multidrug resistant gene 1 ( MDR-1 ) . Gene array analysis extreme drug resistant assay also perform . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients histological diagnosis epithelial ovarian , primary peritoneal , fallopian tube carcinoma previous treatment give . Patients follow histological epithelial cell type eligible : Serous adenocarcinoma Mucinous adenocarcinoma Clear cell adenocarcinoma Transitional cell Adenocarcinoma otherwise specify Endometrioid adenocarcinoma Undifferentiated carcinoma Mixed epithelial carcinoma Malignant Brenner 's tumor Measurable nonmeasurable disease define Solid Tumor Response Criteria ( RECIST ) within 4 week study entry Highrisk surgical candidate Gynecologic Oncology Group ( GOG ) performance status 03 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 1.5 mg/dL Alkaline phosphatase ≤ 3 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Serum glutamic oxaloacetic transaminase ( SGOT ) ≤ 3 time ULN Life expectancy ≥ 12 week Pregnant nursing Positive pregnancy test ( Fertile patient must use effective nonhormonal contraception 3 month completion study treatment . ) History another neoplasm except nonmetastatic , nonmelanoma skin cancer , carcinoma situ cervix , cancer cure surgery &gt; 5 year prior registration . Septicemia , severe infection , acute hepatitis , severe gastrointestinal bleeding , define require blood transfusion hospitalization registration Unstable angina eligible . Patients evidence abnormal cardiac conduction ( e.g . bundle branch block , heart block ) eligible disease stable past six month . History severe hypersensitivity allergic reaction study drug , drug formulate Cremophor EL^® , platinol compound , mannitol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>Brenner tumor</keyword>
</DOC>